血清中非编码RNA SCHLAP1联合PSA在前列腺癌诊断中的价值评估

楚雄师范学院学报 ›› 2021, Vol. 36 ›› Issue (3): 60-66.

血清中非编码RNA SCHLAP1联合PSA在前列腺癌诊断中的价值评估

邹静¹, 唐英², 韩宏¹, 张翠香², 张钰哲^2,3,*

1.大理大学附属第一医院,云南大理 671000;
2.大理大学基础医学院,云南大理 671000;
3.云南昆虫生物医药研发重点实验室,云南大理 671000

收稿日期:2020-11-11 出版日期:2021-05-20 发布日期:2021-07-23
通讯作者: *张钰哲（1980–）,男,博士,大理大学基础医学院讲师,主要研究方向为癌症表观遗传学、生物信息学。Email： Lzuzyz1568@hotmail.com
作者简介:邹静（1985–）,女,在读硕士,主要研究方向为呼吸系统疾病比较诊断学。Email： zoujing786207@163.com
基金资助:
云南省科技厅资助项目（No. 2019FH001）; 云南省昆虫医药研发重点实验室开放项目（No. EBR&D1707）; 大理大学博士科研启动基金项目（No. KYBS2018012）

Evaluation of the Value of Serum Non-coding RNA SCHLAP1 Combined with PSA in the Diagnosis of Prostate Cancer

ZOU Jing¹, TANG Ying², HAN Hong¹, ZHANG Cuixiang

1. First Affiliated Hospital, Dali University, Dali, Yunnan Province 671000;
2. Basic Medical College, Dali University, Dali, Yunnan Province 671000;
3. Yunnan Provincial Key Laboratory of Entomological Biopharmaceutical R&D, Dali, Yunnan Province 671000

Received:2020-11-11 Online:2021-05-20 Published:2021-07-23

摘要/Abstract

摘要： 目的探讨血清非编码RNA SCHLAP1（Non-Coding SCHLAP1）联合前列腺特异性抗原（Prostate Specific Antigen,PSA）检测前列腺癌（Prostate Cancer,PCa）的诊断价值。选取大理大学附属三甲医院2018年4月~2019年8月收治的前列腺癌病人30例（前列腺癌组）、前列腺增生患者60例（前列腺增生组）及健康体检男性30例（健康对照组）,各组均检测血清中SCHLAP1、tPSA及fPSA水平,比较SCHLAP1、总前列腺特异性抗原（tPSA）、游离前列腺特异性抗原（fPSA）、fPSA/tPSA指标的差异,并绘制受试者操作特征曲线（Receiver Operating Characteristic Curve,ROC）,最后然后评估前列腺癌的诊断效能。结果SCHLAP1在前列腺癌组与前列腺增生组、健康对照组组间两两比较差异均有统计学意义（P<0.01）,ROC特征曲线显示,SCHLAP1单独检测诊断的敏感性和特异性分别为76.4%、93.6%,SCHLAP1联合fPSA检测诊断的敏感性和特异性分别为92.0%、88.3%。结论SCHLAP1联合PSA检测可弥补PSA单独检测假阳性高、特异性低的不足,提高前列腺癌诊断的准确性和阳性率。

关键词: 非编码RNA SCHLAP1, 诊断价值, 前列腺肿瘤, 前列腺增生, 前列腺特异抗原

Abstract: Objective:to explore the clinical significance of serum SCHLAP1 and prostate specific antigen (PSA) in detection of patients with prostatic cancer (PCa). Methods:A total of 30 cases of prostate cancer, 30 cases of benign prostate hyperplasia and 30 healthy controls between April 2019 and August 2018 were included in the study. Serum levels of SCHLAP1 and PSA were detected by Biotin labeling probe and RIA, then the cure of the receiver operating characteristics cure (ROC) was drawn, and test results of SCHLAP1, tPSA, fPSA and fPSA/tPSA were compared. Results:The difference of serum SCHLAP1 in patients with prostate cancer, benign prostate hyperplasia and healthy people were statistically significant (P<0.01). ROC showed that the sensitivity and specificity of SCHLAP1 alone were 76.4% and 93.6% respectively, and the sensitivity and specificity of SCHLAP1 joint tPSA detection were 92.0% and 88.3% respectively. Conclusion:The co-detection of SCHLAP1 with PSA can make up for the lack of PSA alone, and improve the accuracy of prostate cancer detection.

Key words: non-coding RNA SCHLAP1, diagnostic value, prostatic neoplasm, prostatic hyperplasia, prostate-specific antigen

中图分类号:

R737.25

邹静, 唐英, 韩宏, 张翠香, 张钰哲. 血清中非编码RNA SCHLAP1联合PSA在前列腺癌诊断中的价值评估[J]. 楚雄师范学院学报, 2021, 36(3): 60-66.

ZOU Jing, TANG Ying, HAN Hong, ZHANG Cuixiang. Evaluation of the Value of Serum Non-coding RNA SCHLAP1 Combined with PSA in the Diagnosis of Prostate Cancer[J]. Journal of Chuxiong Normal University, 2021, 36(3): 60-66.

参考文献

[1] Kim E H, Andriole G L, et al. Prostate cancer review[J]. Modern Medicine, 2018, 115(2): 131.
[2] Alcorn T,Ying H S.Leader of research on prostate cancer in china[J]. Lancet, 2015, 385(9965):321.
[3] 李星,曾晓勇.中国前列腺癌流行病学研究进展[J].肿瘤防治研究,2021,48(1): 98–102.
Li X, zen X Y. Advances in epidemiology of prostate cancer in China[J]. Cancer Research Prevention and Treatment, 2021, 48(1): 98–102.
[4] 何奇瑞,林思浩,王杰,等.局部进展期前列腺癌的诊治进展[J].中国男科学杂志,2020,34(6): 62–66.
He QR, Lin S H, Wang J, et al. Progress in the diagnosis and treatment of locally advanced prostate cancer[J]. Chinese Journal of Andrology, 2020, 34(6): 62–66.
[5] Yanai Y, Kosaka T, Hongo H, et al. Evaluation of prostate-specific antigen density in the diagnosis of prostate cancer combined with magnetic resonance imaging before biopsy in men aged 70 years and older with elevated psa[J]. Molecular And Clinical Oncology, 2018, 9(6): 656–660.
[6] Vilson F L, Li S, Brooks J D, et al. Sudden psa rise to >/=20 ng/ml and prostate cancer diagnosis in the united states: a population-based study[J]. Prostate, 2020, 12(6): 766–772.
[7] Chiu P K, Teoh J Y, Chan S Y, et al. Role of psa density in diagnosis of prostate cancer in obese men[J]. International Urology and Nephrology,2014,46(12): 2251–2254.
[8] Prensner J R, Iyer M K, Sahu A, et al. The long noncoding rna schlap1 promotes aggressive prostate cancer and antagonizes the swi/snf complex[J]. Nature Genetics, 2013, 45(11):1392–1398.
[9] Mehra R, Shi Y, Udager A M, et al. A novel RNA in situ hybridization assay for the long noncoding rna schlap1 predicts poor clinical outcome after radical prostatectomy in clinically localized prostate cancer[J]. Neoplasia , 2014, 16(12): 1121–1127.
[10] Gallo-Oller G, Ordonez R, Dotor J, et al. A new background subtraction method for western blot densitometry band quantification through image analysis software[J]. Journal of Immunological Methods, 2018, 457: 1–5.
[11] Zhang W, Chen Z, Wang WW.Diagnostic value of roc curve evaluating serum related indexes for bloodstream infection in patients with hematopathy[J]. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 2020, 28(5): 1746–1749.
[12] Verbakel J Y, Steyerberg E W, Uno H, et al. Roc curves for clinical prediction models part 1. Roc plots showed no added value above the auc when evaluating the performance of clinical prediction models[J]. Journal Clinical Epidemiology, 2020, 126: 207–216.
[13] Silbert D, Matta N.Roc analysis to improve sensitivity and specificity of the plusoptix photoscreener[J]. Ophthalmic Research, 2012,7(1): 2.
[14] Mallett S, Halligan S, Collins G S, et al. Exploration of analysis methods for diagnostic imaging tests: Problems with roc auc and confidence scores in ct colonography[J]. PLoS One, 2014,9(10): e107633.
[15] Vale C L, Fisher D, Kneebone A, et al. Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data[J]. Lancet,2020,396(10260): 1422–1431.
[16] Fu Z T, Guo X L, Zhang S W, et al. Statistical analysis of incidence and mortality of prostate cancer in china[J]. Zhonghua Zhong Liu Za Zhi,2020, 42(9): 718–722.
[17] Javaeed A, Ghauri S K, Ibrahim A, et al. Prostate-specific antigen velocity in diagnosis and prognosis of prostate cancer - a systematic review[J]. Oncology Reports, 2020,14(1): 449.
[18] VICTORIA J, SHARPM D,ELIZABETH B.TAKACS, M D : Central pain and complex motoric symptoms after gosarelin therapy of prostate cancer. Diagnosis and Treatment, 2010(4): 969–973.
[19] Leskinen MJ, Rantakokko-Jalava K, Manninen R, et al. Negative bacterial polymerase chain reaction (PCR) findings in prostate tissue from patients with symptoms of chronic pelvic pain syndrome (cpps) and localized prostate cancer[J]. Prostate,2003,55(2): 105–110.
[20] Testa U, Castelli G, Pelosi E.Cellular and molecular mechanisms underlying prostate cancer development: Therapeutic implications[J]. Medicines (Basel),2019,6(3): 82.